Australia markets open in 7 hours 1 minute
  • ALL ORDS

    7,442.00
    +23.40 (+0.32%)
     
  • AUD/USD

    0.6711
    +0.0054 (+0.80%)
     
  • ASX 200

    7,253.30
    +24.20 (+0.33%)
     
  • OIL

    78.58
    +1.34 (+1.73%)
     
  • GOLD

    1,770.20
    +14.90 (+0.85%)
     
  • BTC-AUD

    24,438.06
    +202.55 (+0.84%)
     
  • CMC Crypto 200

    387.49
    -1.24 (-0.32%)
     

Got $2,000? Buy These 2 Bear Market-Beating Growth Stocks

Got $2,000? Buy These 2 Bear Market-Beating Growth Stocks

With the market down by more than 21% in 2022, we're officially in a bear market, and many investors are scrambling to protect themselves. AbbVie's (NYSE: ABBV) stock is up 9.9% this year, and with a bunch of recently reported clinical trial results and green lights from regulators, it isn't too surprising why. Most recently, on Sept. 10, it announced that a pair of its phase 3 trials of Skyrizi, a psoriatic arthritis drug that's already on the market, showed that the drug was performing favorably in long-term followup studies.